Evidence map›Paper›PMID 42566288›Full record

ArticleJMIR research protocols2026

Structured Online Support to Inform and Assist Antidepressant Deprescribing in Primary Care (WiserAD Tool): Protocol for a Pragmatic Randomized Controlled Trial.

Catherine Kaylor-Hughes, Amy Coe, Patty Chondros, Konstancja Densley, Susan Fletcher, Mary-Lou Chatterton, Daniel Hoyer, Timothy Chen, Chee Ng, Derelie Mangin and 3 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Catherine Kaylor-HughesDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0003-3353-4108
Amy CoeDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0003-3723-7645
Patty ChondrosDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0003-0393-8734
Konstancja DensleyDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0001-6822-2011
Susan FletcherDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0001-6359-8650
Mary-Lou ChattertonSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-4902-9448
Daniel HoyerDepartment of Biochemistry & Pharmacology, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-1405-7089
Timothy ChenSydney Pharmacy School, University of Sydney, Sydney, Australia.ORCID 0000-0003-4189-8403
Chee NgDepartment of Psychiatry, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-3811-2732
Derelie ManginDepartment of Family Medicine, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-2149-9376
Tony KendrickSchool of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-1618-9381
Zoe AllnuttDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0002-3243-8133
Jane Gunn AoDepartment of General Practice and Primary Care, University of Melbourne, Medical Building, Melbourne, 3010, Australia, 61 3 90355511.ORCID 0000-0001-8836-7525

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The use of antidepressants is increasing globally. Despite their obvious benefits, ongoing use of these medications is often not properly monitored or deprescribed when a person returns to better mental health. In addition, providing prescriptions to those who do not have clinical depression leads to personal and societal cost burdens. Objective: This trial aims to assess the clinical effectiveness and cost-effectiveness of an online support tool designed to help patients with mild to no symptoms of depression and their general practitioners manage the careful and appropriate tapering and cessation of antidepressants at 6 months, and compare the effectiveness to that of usual care. Methods: This stratified, single-blind, parallel, 2-arm, superiority randomized controlled trial includes Australian primary care patients (aged 18-75 years) with mild to no symptoms of depression who have been on antidepressant medication for longer than 12 months. After obtaining informed consent, 340 eligible patients will be randomized in a 1:1 ratio to an active intervention arm and an attention control arm, with stratification by general practice or state of residence, if recruited via social media. Those in the active intervention arm will be asked to reduce their antidepressant use with the aid of a clinically guided online support tool (WiserAD), while those in the attention control arm will continue to receive usual care. Participants in both arms will be provided with information about antidepressants through the Beyond Blue website and followed up at 3, 6, 12, and 18 months to record antidepressant use, depression and anxiety symptom severity, quality of life, and health economic data. An intention-to-treat analysis will determine the clinical effectiveness of the online tool compared with usual care. The primary outcome is the between-arm difference in the proportion of participants who successfully cease medication use at 6 months and have mild or absent depressive symptoms. Cost-consequence and cost-utility analyses will be used to determine the cost-effectiveness of the intervention and its impact on quality of life, and comparisons will be made with usual care. Results: The study was funded by the National Health and Medical Research Council in 2019. At submission of this manuscript in July 2025, 310 participants have been randomized, and recruitment ongoing. The target number of 340 randomized participants was achieved in January 2026. Trial outcomes will be reported in peer-reviewed journals in Febraury 2027. Conclusions: The WiserAD online support tool assists patients and their general practitioners with deprescribing and may lead to successful cessation of antidepressant medication, resulting in enhanced quality of life and cost savings over the longer term.

Indexed as

Antidepressive AgentsDepressionAdolescentAdultAgedAustraliaCost-Benefit AnalysisEquivalence Trials as TopicFemaleHumansMaleMiddle AgedPragmatic Clinical Trials as TopicPrimary Health CareSingle-Blind MethodYoung AdultAntidepressive AgentsantidepressantanxietyAustraliadeprescribingdepressiongeneral practiceGPonlineprimary careRCTsupport tooltapering

Identifiers

PMID42566288
PMCPMC13449978

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.